Based on these mechanisms, targeting the SphK1/S1P/S1PR2 axis could not only suppress tumor proliferation and angiogenesis but also reverse EMT phenotypes and resistance, providing promising intervention strategies for precise HCC treatment. The gene discussed is SPHK1; the disease is neoplasm.